WO2004045632A1 - Ligand du recepteur active de la proliferation des peroxysomes - Google Patents

Ligand du recepteur active de la proliferation des peroxysomes Download PDF

Info

Publication number
WO2004045632A1
WO2004045632A1 PCT/JP2003/014295 JP0314295W WO2004045632A1 WO 2004045632 A1 WO2004045632 A1 WO 2004045632A1 JP 0314295 W JP0314295 W JP 0314295W WO 2004045632 A1 WO2004045632 A1 WO 2004045632A1
Authority
WO
WIPO (PCT)
Prior art keywords
peroxisome proliferator
fennel
activated receptor
animal
extract
Prior art date
Application number
PCT/JP2003/014295
Other languages
English (en)
Japanese (ja)
Inventor
Tozo Nishiyama
Misuzu Tsukagawa
Tatsumasa Mae
Original Assignee
Kaneka Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaneka Corporation filed Critical Kaneka Corporation
Priority to AU2003277665A priority Critical patent/AU2003277665A1/en
Priority to JP2004553154A priority patent/JPWO2004045632A1/ja
Publication of WO2004045632A1 publication Critical patent/WO2004045632A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/235—Foeniculum (fennel)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to a ligand for a peroxisome proliferator-activated receptor (peroxisomeprolyf-e-r-at-or-acti-v-at-t-d-e-rec: PPAR) ligand agent. Further, the present invention provides a prophylactic and / or Z- or ameliorating agent for human or animal hyperlipidemia, diabetes, obesity, inflammation, etc., which comprises a PPAR ligand agent as an active ingredient, and a PPAR ligand agent The present invention relates to a method for preventing and improving or ameliorating hyperlipidemia, diabetes, obesity, inflammation and the like in a human or animal using the same. Background art
  • P PAR is a ligand-dependent transcription factor belonging to the nuclear receptor superfamily, like steroid receptors, retinoid receptors and thyroid receptors.
  • Forms (type, ⁇ (or ⁇ ), type A) have been identified in various animal species, including humans (Proceedings of the National Academic of Sciences, 1992, 89, p. 4653—46 57).
  • PPAR is expressed in the liver, kidney, skeletal muscle, etc., which have high fatty acid catabolism, and is particularly highly expressed in the liver (En docrinology, 1996). 137, p.
  • genes related to fatty acid metabolism and intracellular transport eg, acyl-CoA synthetase, fatty acid binding protein ⁇ lipoprotein lipase, etc.
  • P PAR ⁇ 5 is ubiquitously expressed in various tissues in the body, mainly in nerve cells. At this time, the physiological significance of P PAR ⁇ is unknown.
  • PPARa is highly expressed in adipocytes and is involved in adipocyte differentiation (J ournalof Lipid Research, 1995, Volume 37, p. 907-925). Thus, each isoform of PPAR performs a specific function in a particular organ or tissue.
  • fibrate-based hyperlipidemia therapeutic agents such as Clofi'brate and Bezafibrate
  • fibrate-based hyperlipidemia therapeutic agents have a PPAR ⁇ ligand effect, and are considered to be one of the mechanisms of pharmacological effects.
  • PPARa ligands improve not only lipid metabolism but also glucose metabolism, and have shown effects such as lowering blood lipids, lowering blood glucose levels, and improving insulin sensitivity (Diabetes, 2001 , Volume 50, p. 41 1-41 7), which is considered to be effective also in a state where two or more symptoms such as hyperlipidemia, diabetes mellitus, hyperglycemia, insulin resistance, and obesity occur simultaneously.
  • thiazolidine-based insulin sensitizers are said to exhibit a hypoglycemic effect via PPARr activation (Ayumi, 2001, 198, 747-754).
  • PPARr ligands have been thought to regulate adipocyte differentiation and improve insulin resistance.
  • polyphenols such as monoacylglycerol (Japanese Patent Application Laid-Open No. 2001-354558), gallic acid esters, galloyltannins, quercetin, flavone, isoflavones, catechin and epipicatechin ( Japanese Patent Application Publication No. 2002-80362) is known to have PPAR ligand activity.
  • the PPAR ligand agent is expected to have a preventive and / or Z- or ameliorating effect on many symptoms as mentioned above.
  • the drugs shown above are expensive and have disadvantages such as side effects due to long-term administration.
  • Polyphenols such as monoacylglycerol, gallic acid esters, galloyltannins, quercetin, flavone, isoflavones, catechins and epicatechins have sufficient PPARs. There were inconveniences such as the inability to obtain a gand effect. Therefore, a material having high safety and high PPAR ligand action is desired.
  • the present invention provides a PPAR ligand agent which is derived from natural foods, has no side effects or safety and has high PPAR ligand activity, and a hyperlipidemia comprising the same. It is intended to provide a preventive and / or ameliorating agent for diseases, diabetes, obesity, inflammation and the like. Disclosure of the invention
  • the present inventors have conducted intensive studies to solve the above-mentioned problems, and as a result, have found that an extract of fennel of a plant of the genus Apiaceae has a PPAR ligand activity, and completed the present invention. Reached.
  • the present invention relates to a PPAR ligand agent containing a fennel extract as an active ingredient.
  • the present invention relates to a method for positively or negatively controlling the expression of various genes via human or animal PPAR using the above-mentioned PPAR ligand agent.
  • the present invention provides a method for preventing or preventing one or more symptoms selected from the group consisting of human or animal hyperlipidemia, diabetes, obesity, and inflammation, which comprises the above-mentioned PPAR ligand agent.
  • an ameliorating agent and a method for preventing and / or ameliorating one or more symptoms selected from the group consisting of human or animal hyperlipidemia, diabetes, obesity, and inflammation.
  • Fennel is a perennial herb belonging to the genus Apiaceae, and is one of the herbs commonly used in fish dishes.
  • the Japanese name is ikiyo, which is used as a diuretic, expectorant, carminative, and stomachic.
  • the water extract and the 50% ethanol extract have a blood pressure lowering effect (Proceedings of the National Academic of Sciences, 1999, Vol. 89, p. 4653-4657, Japanese patent application publication) 200 1—335494), the ethanol extract has antioxidant activity (see Japanese Patent Application Publication No. 299151, 1994), and is used as a water or water-soluble polar organic solvent extract. Has the effect of suppressing liver injury (Japanese Patent Application Publication No. 2001-72599) And so on).
  • fennel extract is known to have an anti-inflammatory effect due to inhibition of 3-hydroxysteride dehydrogenase or hyaluronidase (see Japanese Patent Application Publication No. 318887/1999).
  • PPAR ligand activity in fennel extracts.
  • the present action has a preventive and / or ameliorating effect on hyperlipidemia, diabetes, obesity, and inflammation.
  • the PPAR ligand agent of the present invention contains a fennel extract as an active ingredient.
  • the extract of fennel of the present invention include sweet fennel (Sweet Fennel 1), bronze fennel (Bronze Fennell), Florence Fennenel, and bitter fennel (Bitter Fennell). ), An extract of German Fennell 1 can be used.
  • the extract of fennel used in the present invention is preferably a plant extract of sweet fennel, bronze fennel or Florence fennel from the viewpoint of availability.
  • the PPAR ligand agent referred to in the present invention is a substance containing a compound having an ability to bind to a PPAR ligand binding region, that is, a PPAR ligand activity.
  • the PPAR ligand agent of the present invention becomes an important regulator of many physiological functions including glucose and lipid metabolism via PPAR, and prevents and / or ameliorates hyperlipidemia, diabetes, obesity, inflammation, etc. be able to. That is, the PPAR ligand agent of the present invention can positively or negatively regulate the expression of various genes related to hyperlipidemia, diabetes, obesity, inflammation and the like. Examples of the various genes include, but are not limited to, acyl CoA synthase, fatty acid binding protein, lipoprotein lipase, and apolipoprotein.
  • PPAR ligand activity can be measured, for example, by using a reporter to evaluate the binding of the PPAR ligand-binding domain to the GAL4 fusion protein by luciferase expression. Competition binding using a protein containing a PPAR ligand binding region (Cell, 1995, vol. 83, p. 803-812), and Atssei (Cell, 1995) , Pp. 83, p. 81 3—8 19). In these assays, the activity of the sample is generally higher than that of the solvent control, and the sample that shows higher activity than the solvent control and is dose-dependent is evaluated as having “PPAR ligand activity”.
  • the method for obtaining the extract of the present invention from fennel includes, for example, a method by solvent extraction.
  • the extraction operation is not limited to the solvent extraction, but may be an extraction operation such as steam distillation or extraction with carbon dioxide using a supercritical extraction technique.
  • the extract can be used in the present invention as an extract, or as a crude extract or a semi-purified extract, as long as it does not contain impurities that are unsuitable for foods and drinks and pharmaceuticals.
  • the solvent used for the extraction is preferably a safe solvent that can be used for the production and processing of foods, food additives, pharmaceuticals, etc., for example, water, ethanol, acetone, glycerin, ethyl acetate, propylene glycol, hexane, edible oils, etc. And two or more of these may be used as a mixture.
  • organic solvents such as ethanol, acetone, ethyl acetate, and hexane are preferable in terms of easy removal of the solvent after extraction, and ethanol is more preferable in terms of safety of the residual solvent.
  • fennel is immersed in 1 to 20 times the amount of the above solvent, stirred or left, and filtered or centrifuged to obtain an extract. Next, the solvent may be removed from the obtained extract.
  • the fennel for extraction may be raw or dried, but preferably dried from the viewpoint of storage.
  • the form of the fennel may be any of a prototype, pulverized, cut, or powder.
  • the extraction temperature is generally -20 to 100 ° C, usually 1 to 80 ° C, preferably 20 to 60 ° C.
  • the extraction time is usually 0.1 hour to 1 month, preferably 0.5 hour to 7 days.
  • the plant parts used for obtaining the fennel extract are not particularly limited, and any of whole plants, leaves, stems, roots, flowers, seeds and the like may be used.
  • the form of the extract of the present invention may be in the form of an extract or may be a form from which the solvent has been removed. Further, it may be dissolved and suspended in a suitable solvent. These extracts have PPAR ligand activity, and can be subjected to deodorization, purification, and other operations within a range not losing PPAR ligand activity.
  • the PPAR ligand agent of the present invention contains the above-mentioned fennel extract as an active ingredient, and may contain an effective amount in a range that can exhibit PPAR ligand activity.
  • the hyperlipidemia, diabetes, obesity, inflammation prevention and Z or ameliorating agent of the human or animal of the present invention comprises a PPAR ligand agent as described above.
  • a prophylactic and / or ameliorating agent for one or more symptoms selected from the group consisting of hyperlipidemia, diabetes, obesity, and inflammation is used as a prophylactic and / or ameliorating agent for each of these symptoms alone. It may be used, or may be used as a preventive and / or ameliorating agent for a condition in which two or more of these symptoms occur simultaneously.
  • the prevention of hyperlipidemia is defined as the ⁇ lipidemia state or boundary defined by the Japan Atherosclerosis Society in the guidelines for the management of atherosclerotic diseases (issued in September 2002). To prevent or delay the state of the territory.
  • the improvement of hyperlipidemia means that the hyperlipidemia state or the boundary area state described above is brought closer to the state defined as the normal area in the above-mentioned guidelines.
  • the prevention of diabetes is defined as the diabetes condition or boundary area defined by the Diabetes Society of Japan in the Diabetes Treatment Guidebook 202-202 (issued in May 2002). Refers to preventing or delaying a condition.
  • the improvement of diabetes refers to bringing the hyperlipidemia state or the boundary area state closer to the state defined as a normal area in the above guide.
  • prevention of obesity is defined as obesity or obesity in the Obesity Society of Japan Obesity Guidance Manual 2nd Edition (issued in July 2001) by the Japan Obesity Society. Refers to preventing or delaying a condition. Further, the improvement of obesity refers to a situation in which the above-mentioned society defines obesity or obesity to approach a state where the above-mentioned society defines a normal range.
  • the inflammation PPAR is involved, inflammation via Roikotoryen B 4, inflammatory cytokines Ya protein in cells such as macrophages (e.g., TNF-a, IL one l j3, IL one 6, NO synthase , Gelatinase B, Scavenger Recept (Yuichi) refers to inflammation and the like.
  • macrophages e.g., TNF-a, IL one l j3, IL one 6, NO synthase , Gelatinase B, Scavenger Recept (Yuichi) refers to inflammation and the like.
  • prevention of inflammation refers to preventing or delaying the above-mentioned symptoms of inflammation.
  • amelioration of inflammation refers to recovering or reducing the above-mentioned symptoms of inflammation.
  • the PPAR ligand agent of the present invention and the agent for preventing and / or ameliorating hyperlipidemia, diabetes, obesity, and inflammation in humans or animals containing the same can be used for eating and drinking and for medicine.
  • the form is not limited.
  • health foods special health foods, nutritional foods
  • nutritional foods, foods and drinks such as dietary supplements
  • easily available drugs such as over-the-counter drugs (OTC) or pharmaceutical departments It can be used as a foreign product.
  • OTC over-the-counter drugs
  • the PPAR ligand agent of the present invention or the agent for preventing and / or ameliorating hyperlipidemia, diabetes, obesity, and inflammation in humans or animals containing the same is used as a food or drink, it can be directly taken as it is.
  • known additives such as carriers and auxiliaries, capsules, tablets, granules and the like can be ingested and ingested.
  • the content of the preventive and / or ameliorating agent for hyperlipidemia, diabetes, obesity, and inflammation of the present invention in these molding agents is preferably calculated as an extract of fennel, which is an active ingredient (dry weight, the same applies hereinafter). 0.1 to 100% by weight, more preferably 10 to 90% by weight.
  • confectionery such as chewing gum, chocolate, candy, jelly, biscuit, cracker, etc .
  • ice confectionery such as ice cream, ice confectionery
  • tea, soft drink, nutritional drink, beauty Beverages such as drinks
  • kneaded products such as kama, bamboo rings, and hanpon
  • seasonings such as dressings, mayonnaise, and sauces
  • It can be used for all foods and drinks such as bread, ham, soup, retort food, frozen food.
  • the amount of the extract is preferably 0.01 to 100 OmgZkg body weight per adult per day as the extract. , More preferably 0.1 to 1 00 mg / kg body weight.
  • the dosage form is not particularly limited.
  • capsules, tablets, granules, injections, suppositories, patches and the like can be mentioned.
  • other pharmaceutically acceptable pharmaceutical ingredients such as excipients, disintegrants, lubricants, binders, antioxidants, coloring agents, antiaggregants, absorption promoters, dissolution aids It can be prepared by appropriately adding agents, stabilizers and the like.
  • the dosage of these preparations is preferably 0.01 to: LOO OmgZkg body weight, more preferably 0.1 to 10 Omg / kg body weight per day per adult in terms of the extract, divided into one or several doses. Administration.
  • the PPAR ligand agent of the present invention and the agent for preventing and improving Z or amelioration of hyperlipidemia, diabetes, obesity, and inflammation in humans or animals containing the same are used as quasi-drugs, if necessary, Additives such as ointments, liniments, aerosols, creams, stones, facial cleansers, body cleansers, lotions, lotions, baths, etc. Can be used.
  • Additives such as ointments, liniments, aerosols, creams, stones, facial cleansers, body cleansers, lotions, lotions, baths, etc. Can be used.
  • the present invention will be described more specifically with reference to Examples, but the present invention is not limited to these Examples.
  • CV-1 cells (cultured cells from male African green monkey kidney (ATCC CCL 70 obtained from American Evening Culture Collection) should be placed in a 96-well culture plate at 6 ⁇ 10 3 ce 11 s / we 11 the implantation, were cultured for 24 hours at 37 ° C, 5% C_ ⁇ 2 under conditions in.
  • the culture medium 1 0% FB S ( ⁇ shea calf serum), 1 0 m l ZL Benishirin-stress but-mycin solution (each 500 0 DMEM (Dulbecco's Modified E) containing IU / m1, 5000 Mg / m1, GIB CO; US (now Invitrogen)), 37 mg ZL ascorbic acid (Wako Pure Chemical Industries, Ltd .; Japan)
  • OPT I-MEM registered trademark, GI BCO
  • pM-PPARa and 4xUAS were used.
  • g-luc was transfected using Lipofect AMINE-PLUS (registered trademark, GI BCO).
  • PBS + phosphate buffered saline
  • PM-PPARr is a plasmid in which the chimeric protein gene in which the yeast-derived transcription factor GAL4 gene (amino acid sequence 1-147) and the human PPART ligand binding site gene (amino acid sequence 174-475) are linked to pM is inserted. It is. Troglitazone (Sankyo Co., Ltd .; Japan) was used as a positive control. Table 2 shows the results. Table 2
  • Example 2 40 parts by weight of the ethanol extract of fennel obtained in Example 1, 30 parts by weight of sodium carboxymethylcellulose, 20 parts by weight of crystalline cellulose, and 10 parts by weight of vitamin C were mixed and ground. Then, the mixture was filled into gelatin capsules (size: No. 02, Riki Busgel Japan K.K.) to prepare capsules for eating and drinking containing the extract at 40% by weight.
  • gelatin capsules size: No. 02, Riki Busgel Japan K.K.
  • Example 1 The effect of the fennel extract of Example 1 was evaluated as follows using a hyperlipidemia (hyperneutral lipemia) model / rat that develops when fructose water is given to SD lad. Bezafibrate, a drug for treating hyperlipidemia, was used as a positive control.
  • hyperlipidemia hyperneutral lipemia
  • SD rats (oss, 6 weeks old) were divided into three groups (six in each group), and each was given 25% (w / v) fructose water as drinking water.
  • the experimental animal powder feed (CE-2, CLEA Japan; Japan) was used as a basic feed, and a non-supplemented group (control group), a bezafibrate-added group, and a fennel extract-added group were fed freely for one week.
  • Bezafibrate is obtained by pulverizing Bezator 20 Omg tablets (containing 20 Omg of bezafibrate per tablet, Kitssei Pharmaceutical Co., Ltd .; Japan) and adding bezafibrate It was added to the powdered feed so that the added amount was 0.01% (w / w). The fennel extract was added to the powdered feed so that the amount added was 0.2 (w / w).
  • the PPAR ligand agent of the present invention has excellent PPAR ligand activity.
  • it is highly safe because it is derived from food materials, is useful for preventing and / or improving hyperlipidemia, diabetes, obesity, and inflammation, and has functional health foods (specified health foods, nutritional foods), and health. It can be used as foods and drinks such as dietary supplements, or easily available drugs or quasi-drugs such as OTC.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Emergency Medicine (AREA)
  • Botany (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

L'invention concerne un ligand du récepteur activé de la prolifération des peroxysomes (PPAR) contenant, comme ingrédient actif, un extrait de fenouil, qui est une substance alimentaire saine. Ce ligand PPAR présente une excellente activité et est destiné à la prévention et/ou au traitement de l'hyperlipidémie, du diabète, de l'obésité et des inflammations. De préférence, le fenouil utilisé est sélectionné dans le groupe comprenant du fenouil doux, du fenouil bronze, du fenouil de Florence, du fenouil amer et du fenouil allemand. Mieux encore, l'extrait utilisé est extrait du fenouil à l'aide un solvant (de l'éthanol, de préférence). Idéalement, l'extrait utilisé est extrait d'une poudre de fenouil sèche.
PCT/JP2003/014295 2002-11-12 2003-11-11 Ligand du recepteur active de la proliferation des peroxysomes WO2004045632A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2003277665A AU2003277665A1 (en) 2002-11-12 2003-11-11 Peroxisome proliferator-activated recetor ligand
JP2004553154A JPWO2004045632A1 (ja) 2002-11-12 2003-11-11 ペルオキシソーム増殖剤応答性受容体リガンド剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002328652 2002-11-12
JP2002-328652 2002-11-12

Publications (1)

Publication Number Publication Date
WO2004045632A1 true WO2004045632A1 (fr) 2004-06-03

Family

ID=32321626

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2003/014295 WO2004045632A1 (fr) 2002-11-12 2003-11-11 Ligand du recepteur active de la proliferation des peroxysomes

Country Status (4)

Country Link
JP (1) JPWO2004045632A1 (fr)
AU (1) AU2003277665A1 (fr)
TW (1) TW200507865A (fr)
WO (1) WO2004045632A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007070355A3 (fr) * 2005-12-09 2008-07-03 Metaproteomics Llc Produits botaniques anti-inflammatoires pour le traitement du syndrome metabolique et du diabete
JP2009521401A (ja) * 2005-10-28 2009-06-04 ビーエーエスエフ、ビューティー、ケア、ソルーションズ、フランス、エスエーエス Ｌｏｘタンパク質とｎｒａｇｅタンパク質との通常の共発現と相互作用を復元させる物質
JP2011037907A (ja) * 2004-03-30 2011-02-24 Soda Aromatic Co Ltd アラキドン酸代謝抑制剤
US8206753B2 (en) 2001-06-20 2012-06-26 Metaproteomics, Llc Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes
JP2015086168A (ja) * 2013-10-30 2015-05-07 株式会社ブルーム・クラシック リパーゼ阻害剤および皮脂コントロール用皮膚化粧料
WO2024038335A1 (fr) * 2022-08-18 2024-02-22 GUPTE, Vaidehi Korde Formulations nutraceutiques pour combattre des affections liées au poids

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09502196A (ja) * 1993-09-10 1997-03-04 バイヤースドルフ・アクチエンゲゼルシヤフト 植物油類の使用法
WO1999047110A1 (fr) * 1998-03-16 1999-09-23 Unilever Plc Procede cosmetique de traitement de la peau
JP2000511942A (ja) * 1997-07-05 2000-09-12 ガルデルマ・ソシエテ・アノニム 炎症治療用のペトロセリン酸の使用
WO2001008653A1 (fr) * 1999-07-30 2001-02-08 Unilever Plc Composition pour soins de la peau
WO2002051428A1 (fr) * 2000-12-25 2002-07-04 Shiseido Company, Ltd. Composition de parfum stimulant le systeme sympathique

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09502196A (ja) * 1993-09-10 1997-03-04 バイヤースドルフ・アクチエンゲゼルシヤフト 植物油類の使用法
JP2000511942A (ja) * 1997-07-05 2000-09-12 ガルデルマ・ソシエテ・アノニム 炎症治療用のペトロセリン酸の使用
WO1999047110A1 (fr) * 1998-03-16 1999-09-23 Unilever Plc Procede cosmetique de traitement de la peau
WO2001008653A1 (fr) * 1999-07-30 2001-02-08 Unilever Plc Composition pour soins de la peau
WO2002051428A1 (fr) * 2000-12-25 2002-07-04 Shiseido Company, Ltd. Composition de parfum stimulant le systeme sympathique

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BELLOMARI B. ET AL.: "Essential oil of foeniculum vulgare mill.ssp.vulgare", RIVISTA ITALIANA EPPOS, no. 27, 1999, pages 43 - 48 *
DATABASE CAPLUS [online] XP002979119, Database accession no. (1999:695354) *
GOTO TSUYOSHI ET AL.: "PPAR kassei seigyo no kansuru shokuhin seibun no kensaku to sono kino hyoka", THE JAPANESE SOCIETY OF NUTRITION AND FOOD SCIENCE SOKAI KOEN YOSHISHU, vol. 56, 20 June 2002 (2002-06-20), pages 311, XP002979117 *
NORISADA YOSHINOBU ET AL.: "PPAR PPAR no ligand to kassei kayaku", ENSHO TO MEN'EKI, vol. 10, no. 3, May 2002 (2002-05-01), pages 281 - 287, XP002979118 *
ONO MASATERU ET AL.: "Antioxidative and antihyaluronidase activities of some constituents from foeniculi fructus (fruit of foeniculum vulgare MILLER)", FOOD SCI. TECHNOL. INT., vol. 3, no. 1, 1997, TOKYO, pages 53 - 55, XP002979116 *
SHO HIROKO ET AL.: "The possible effects of dietary components of okinawan cuisine on longevity (Okina wagata no shokuseikatsu)", REPORTS OF THE RESEARCH COMMITTEE OF ESSENTIAL AMINO ACIDS, no. 123, 1992, pages 25 - 32, XP002979115 *
TAKAHASHI NOBUYUKI ET AL.: "Dual action of isoprenols herbal medicines on both PPARgamma and PPARalpha in 3T3-L1 adipocytes and HeG2 hepatocyte", FEBS LETTERS, vol. 514, no. 2-3, 13 March 2002 (2002-03-13), pages 315 - 322, XP004347719 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8206753B2 (en) 2001-06-20 2012-06-26 Metaproteomics, Llc Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes
JP2011037907A (ja) * 2004-03-30 2011-02-24 Soda Aromatic Co Ltd アラキドン酸代謝抑制剤
JP2009521401A (ja) * 2005-10-28 2009-06-04 ビーエーエスエフ、ビューティー、ケア、ソルーションズ、フランス、エスエーエス Ｌｏｘタンパク質とｎｒａｇｅタンパク質との通常の共発現と相互作用を復元させる物質
JP2015028036A (ja) * 2005-10-28 2015-02-12 ビーエーエスエフ、ビューティー、ケア、ソルーションズ、フランス、エスエーエス Ｌｏｘタンパク質とｎｒａｇｅタンパク質との通常の共発現と相互作用を復元させる物質
US9308161B2 (en) 2005-10-28 2016-04-12 Basf Beauty Care Solutions France S.A.S. Substance for restoring normal co-expression and interaction between the LOX and NRAGE proteins
WO2007070355A3 (fr) * 2005-12-09 2008-07-03 Metaproteomics Llc Produits botaniques anti-inflammatoires pour le traitement du syndrome metabolique et du diabete
JP2015086168A (ja) * 2013-10-30 2015-05-07 株式会社ブルーム・クラシック リパーゼ阻害剤および皮脂コントロール用皮膚化粧料
WO2024038335A1 (fr) * 2022-08-18 2024-02-22 GUPTE, Vaidehi Korde Formulations nutraceutiques pour combattre des affections liées au poids

Also Published As

Publication number Publication date
JPWO2004045632A1 (ja) 2006-03-16
AU2003277665A1 (en) 2004-06-15
TW200507865A (en) 2005-03-01

Similar Documents

Publication Publication Date Title
US10646498B2 (en) Composition for preventing, alleviating or treating muscle diseases or improving muscular function
JP5563824B2 (ja) ペルオキシソーム増殖剤応答性受容体（ｐｐａｒ）のリガンド剤
JP2010106001A (ja) Ｐｐａｒ活性化剤
AU2020200225A1 (en) Composition for improvement of muscle function containing 3,5-dicaffeoylquinic acid or chrysanthemum extract
JP6688492B2 (ja) 黒生姜含有ＰＰＡＲγ発現促進組成物
JP2012149004A (ja) 核内受容体の賦活剤
JP2008163014A (ja) １１βＨＳＤ１阻害剤及びその用途
JP2006335741A (ja) アモルフォファルス属植物由来ペルオキシソーム増殖剤応答性受容体リガンド組成物
JP2004161656A (ja) ペルオキシソーム増殖剤応答性受容体リガンド剤
WO2004045632A1 (fr) Ligand du recepteur active de la proliferation des peroxysomes
JP2006273788A (ja) Ｐｐａｒリガンド活性を有する植物由来の組成物
JP2007314475A (ja) トリアシルグリセロール合成抑制剤
KR101851639B1 (ko) 모과 추출물 또는 이의 분획물을 유효성분으로 함유하는 항비만용 조성물
JP2009203209A (ja) アカシア属樹皮由来物を含有する血糖降下及び／又は抗肥満組成物
JP2005295991A (ja) Ｐｐａｒ活性化作用を有する健康食品およびｐｐａｒ活性化剤
KR20070044198A (ko) 푸마르산 및 푸마르산 유도체를 유효성분으로 함유하는대사증후군 치료제
JP5004529B2 (ja) ヒスタミン遊離抑制剤
JP2009249331A (ja) 植物由来の高脂血症の予防または改善剤
JP2010105923A (ja) アカシア属樹皮由来物を含有するＰＰＡＲδ発現促進剤
JP2007022917A (ja) Ｐｐａｒリガンド活性を有する植物由来の組成物
JPWO2005082391A1 (ja) ヒトβ３アドレナリン受容体アゴニスト剤
WO2005053675A1 (fr) Composition comprenant un compose alcool isole a partir d'un extrait vegetal de la famille des cucurbitacees, presentant une activite anti-adipogene et anti-obesite
JP4809611B2 (ja) 脂肪細胞の脂肪蓄積阻害剤
JP2005320292A (ja) ペルオキシソーム増殖剤応答性受容体リガンド剤
KR20210051122A (ko) 마리안 플럼 추출물을 포함하는 PPARα에 의해 매개되는 질환의 예방, 개선 또는 치료용 조성물

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004553154

Country of ref document: JP

122 Ep: pct application non-entry in european phase